ENTITY
Acadia Pharmaceuticals

Acadia Pharmaceuticals (ACAD US)

26
Analysis
Health CareUnited States
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company is currently working on the treatment of induced dysfunction in Parkinson's disease ,schizophrenia, neuropathic pain and glaucoma.
more
21 Dec 2023 09:30

2023 in Rear Mirror View: Top Performers From My Global Healthcare Coverage Universe

​Despite ongoing recovery and fading effect of the COVID-19, healthcare companies had varying performances in 2023. From my coverage, the top...

Logo
603 Views
Share
20 Oct 2024 07:30

APAC Healthcare Weekly (Oct 20)- Eisai, Daiichi Sankyo, Junshi Bioscience, Akeso, Celltrion, Neuren

This insight collates key news in APAC healthcare last week. With the earnings season beginning to unfold along with major pharma and healthcare...

Logo
334 Views
Share
05 Sep 2024 23:44

Neuren Pharmaceuticals (NEU AU): Ready to Fly Again After a Breather

​Neuren shares dip due to disappointing U.S. performance of Daybue. Muted US performance of Daybue in 1H24 seems to be short-lived and the drug is...

Logo
372 Views
Share
20 Dec 2023 09:30

Neuren Pharmaceuticals (NEU AU): Positive Trial Result- A Step Ahead for Potential Second Drug

​Neuren announced positive phase 2 trial results for NNZ-2591 in Phelan-McDermid syndrome, a genetic disorder. NNZ-2591 has the potential to become...

Logo
408 Views
Share
14 Jul 2023 23:20

Neuren Pharmaceuticals (NEU AU): Shares Roar on Expanded Global Partnership for Newly Launched Drug

Neuren expanded Acadia’s trofinetide license to worldwide, for up to additional $527M to Neuren (including $100M up-front) plus mid-teens to low...

Logo
424 Views
Share
x